Heather Wakelee

Professor

Stanford University
Country flagUnited States
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (14)

A) ORR (left), PFS (middle) and OS (right) in patients with ECOG-PS 0 or 1, at least 1 prior line of therapy for metastatic disease and without untreated brain metastases; B) Survival outcomes in patients with treated or untreated brain metastases prior to starting KRAS G12Ci; C) Survival outcomes according to PD-L1 status (TPS: tumor proportion score); D) survival outcomes in patients with or without prior immune checkpoint inhibitor therapy.

Year:

2025

A) Survival outcomes in patients with additional RAS co-alterations (KRAS amplification, other KRAS, NRAS and/or HRAS somatic mutations) in the KSCWT population; B) outcomes according to AKT1/PIK3CA/MTOR/TSC1/2/PTEN co-mutation status for all patients evaluable for these co-alterations; survival outcomes according to ALK, ROS1, NTRK1-3 co-mutation status in C) all mutation-evaluable patients, and D) limiting the analysis to the KSC WT population.

Year:

2025

Survival outcomes according to KEAP1 and STK11 co-mutation status: A) Cohort A; B) Cohort B; C) further subclassifying KEAP1MUT tumors according to STK11 mutation status; D) PFS and OS according to STK11 co-mutation status in KSCWT tumors in the overall study cohort.

Year:

2025

A) Venn diagram depicting co-mutation overlap between KEAP1, SMARCA4, and CDKN2A – KSC genes; survival outcomes according to co-mutation overlap in any of the KSC genes - PFS (B) and OS (C). Only patients whose tumor was profiled with a NGS panel providing coverage for all 3 genes were included in this analysis.

Year:

2025

Figures showing the CONSORT diagram, clonal hematopoiesis prevalence, the SNV score model, mid-chemoradiation ctDNA analysis, radiomic model robustness, pre-chemoradiation prognostic factors, association of clonal hematopoiesis with outcomes, and association of the CIRI-LCRT model with progression-free survival.

Year:

2025

The complementarity and clinical utility of combining liquid biopsies and radiomic image analysis has not been demonstrated. ctDNA minimal residual disease after chemoradiotherapy (CRT) for non–small cell lung cancer (NSCLC) is highly prognostic, but on-treatment biomarkers are needed to enable response-adapted therapies. In this study, we analyzed 418 patients with NSCLC undergoing CRT to develop and validate a novel dynamic risk model that accurately predicts ultimate progression-free survival during treatment. We optimize tissue-free variant calling from plasma samples to facilitate ctDNA monitoring and demonstrate the importance of accounting for persistent clonal hematopoiesis variants. We show that mid-CRT ctDNA concentration is prognostic for disease progression and integrate additional pre-CRT risk factors, including radiomics, into a combined model that improves outcome prediction. Our results suggest that tumor features, radiomics, and mid-CRT ctDNA analysis are complementary and can identify patients at high and low risk of progression to potentially enable response-adapted therapies. Significance: This study demonstrates that combining tumor features, radiomics, and ctDNA analysis improves outcome prediction in NSCLC treated with CRT therapy. Our integrated model could enable personalized and response-adapted therapies to reduce toxicity and improve outcomes in patients. See related commentary by Anagnostou and Aggarwal, p. 1534

Year:

2025

A) ORR (left), PFS (middle) and OS (right) in patients with ECOG-PS 0 or 1, at least 1 prior line of therapy for metastatic disease and without untreated brain metastases; B) Survival outcomes in patients with treated or untreated brain metastases prior to starting KRAS G12Ci; C) Survival outcomes according to PD-L1 status (TPS: tumor proportion score); D) survival outcomes in patients with or without prior immune checkpoint inhibitor therapy.

Year:

2024

A) Venn diagram depicting co-mutation overlap between KEAP1, SMARCA4, and CDKN2A – KSC genes; survival outcomes according to co-mutation overlap in any of the KSC genes - PFS (B) and OS (C). Only patients whose tumor was profiled with a NGS panel providing coverage for all 3 genes were included in this analysis.

Year:

2024

A) Survival outcomes in patients with additional RAS co-alterations (KRAS amplification, other KRAS, NRAS and/or HRAS somatic mutations) in the KSCWT population; B) outcomes according to AKT1/PIK3CA/MTOR/TSC1/2/PTEN co-mutation status for all patients evaluable for these co-alterations; survival outcomes according to ALK, ROS1, NTRK1-3 co-mutation status in C) all mutation-evaluable patients, and D) limiting the analysis to the KSC WT population.

Year:

2024

A) Survival outcomes in patients with additional RAS co-alterations (KRAS amplification, other KRAS, NRAS and/or HRAS somatic mutations) in the KSCWT population; B) outcomes according to AKT1/PIK3CA/MTOR/TSC1/2/PTEN co-mutation status for all patients evaluable for these co-alterations; survival outcomes according to ALK, ROS1, NTRK1-3 co-mutation status in C) all mutation-evaluable patients, and D) limiting the analysis to the KSC WT population.

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Collaborators (40)

Mark Awad

Chief, Thoracic Oncology Service

Memorial Sloan Kettering Cancer Center

UNITED STATES
View details

Jianjun Zhang

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Neal Akhave

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Christine Bestvina

Assistant Professor

University of Chicago Medicine

UNITED STATES
View details

Sandip Patel

Associate Professor

Moores Cancer Center, UC San Diego Health

UNITED STATES
View details

Marina Garassino

Prof

Università degli Studi di Torino

ITALY
View details

Jacobi Hines

Assistant Professor

Northwestern Medicine

UNITED STATES
View details

Qi Wang

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Mizuki Nishino

King’s College London

UNITED STATES
View details

Petros Christopoulos

-

GERMANY
View details

Yufei Liu

Assistant Clinical Professor

City of Hope

UNITED STATES
View details

Everett J. Moding

Stanford University

UNITED STATES
View details

Amy L Cummings

UCLA School of Medicine

UNITED STATES
View details

Ruijiang Li

Associate Professor

Stanford University

UNITED STATES
View details

Giorgio V Scagliotti

Chair

University of Turin

ITALY
View details

james hicks

H Lee Moffitt Cancer Center and Research Institute

UNITED STATES
View details

Arash Ash Alizadeh

Professor of Medicine

Stanford University School of Medicine

UNITED STATES
View details

Mingjia Li

Assistant Professor

Ohio State University

UNITED STATES
View details

Maximilian Diehn

Professor

Stanford University

UNITED STATES
View details

Collin Blakely

Assistant Professor

UCSF Medical Center

UNITED STATES
View details

Matthias Scheffler

University Hospital Bonn

GERMANY
View details

Kavitha Ramchandran

Clinical Associate Professor

Stanford University

UNITED STATES
View details

John V. Heymach

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

J. Jack Lee

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Aadel A. Chaudhuri

Washington University School of Medicine

UNITED STATES
View details

Steven Lin

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Jing Wang

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

David S. Hong

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Funda Meric-Bernstam

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

David Kurtz

Assistant Professor

Stanford University

UNITED STATES
View details

Ying Ni

Assistant Professor

Case Western Reserve University

UNITED STATES
View details

Catherine Shu

Columbia University Irving Medical Center

UNITED STATES
View details

Ferdinandos Skoulidis

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Albrecht Stenzinger

-

GERMANY
View details

Billy Loo

Professor

Stanford University

UNITED STATES
View details

Michael F. Gensheimer

Stanford University School of Medicine

UNITED STATES
View details

Marcelo Negrao

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Don L. Gibbons

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Dwight H. Owen

Ohio State University

UNITED STATES
View details

Mohammad Shahrokh Esfahani

Assistant Professor

Stanford University

UNITED STATES
View details